Showing 2491-2500 of 23150 results for "".
Multiple Eruptive Myxoid Dermatofibromas in Patient With History of HIV
https://reachmd.com/programs/practical-dermatology/multiple-eruptive-myxoid-dermatofibromas-in-patient-with-history-of-hiv/24216/Multiple eruptive dermatofibromas, a rare presentation of dermatofibroma, has been associated with altered immunity such as HIV/AIDS.Living With Systemic Mastocytosis: Bridging Clinical Decisions and Patient Realities
https://reachmd.com/programs/cme/living-with-systemic-mastocytosis-bridging-clinical-decisions-and-patient-realities/54389/Join us to explore the disease burden of systemic mastocytosis, evidence-based personalized care, and using multidisciplinary strategies to improve outcomes.Shielding Your Wealth From Potential Liability
https://reachmd.com/ma-issues-index/2022-nov-dec/shielding-your-wealth-from-potential-liability/35233/The basics of a solid asset protection plan.Radium-223’s Potential Quality of Life Benefits for mCRPC Patients
https://reachmd.com/programs/project-oncology/radium-223s-potential-quality-of-life-benefits-for-mcrpc-patients/28642/Dive into a study that explored how radium-223 may be able to boost the quality of life of patients battling metastatic castration-resistant prostate cancer.Personalizing PNH Care: Exploring the Role of Iptacopan in Clinical Practice
https://reachmd.com/programs/medical-industry-feature/personalizing-pnh-care-iptacopan/35650/While patients with paroxysmal nocturnal hemoglobinuria (PNH) share the same diagnosis, they show a range of hemoglobin levels and symptoms.1,2 C5 inhibitors have reduced mortality and morbidity in patients with PNH, but FABHALTA® (iptacopan) may offer another treatment option that can match individHarness Empathy to Connect with Patients on a Deeper Level
https://reachmd.com/topics/practice-development/harness-empathy-to-connect-with-patients-on-a-deeper-level/35169/Listening, respect, and a focus on the patient are keySustaining Vision: Empowering Optometry for Tomorrow’s Retinal Care
https://reachmd.com/cme/ophthalmology/Sustaining-Vision-Empowering-Optometry-for-Tomorrows-Retinal-Care/32392/Join Drs. Khanani, Sheth, and Vajzovic, to learn how to educate patients about alternative treatment options for retinal diseases.Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors
https://reachmd.com/programs/cme/navigating-today-and-shaping-tomorrow-in-ism-personalized-strategies-with-current-and-emerging-kit-inhibitors/54388/Explore the latest clinical evidence on current and emerging KIT tyrosine kinase inhibitors in indolent systemic mastocytosis to optimize patient care.Rewiring Your Thinking in Paroxysmal Nocturnal Hemoglobinuria
https://reachmd.com/programs/medical-industry-feature/rewiring-your-thinking-in-paroxysmal-nocturnal-hemoglobinuria/35648/As of the past few years, there are more options to consider when treating adult patients with paroxysmal nocturnal hemoglobinuria (PNH).1-5 Some providers note that in light of these shifts, they can focus on tailoring their treatment decisions to fit the specific needs of their patients. Join StevHarnessing the NAFLD/NASH Epidemic: Preparing for a New Treatment Paradigm
https://reachmd.com/programs/cme/harnessing-the-nafldnash-epidemic-preparing-for-a-new-treatment-paradigm/15673/Do you understand your role in determining which patient may benefit the most from NASH therapy?